"There are only two ways to become a leader: one is low-balling the price which entails huge risks brought in by lack of any security of guarantees, and the second one is to create new products and services that make you able to out-compete others and become the best partner our clients want. Implementing the second option that is going to be priority for FC Grand Capital for the next few years has been entrusted to Yulia Lipkina who proved her abilities beyond any doubt while she was working as the Commercial Director," said Denis Remenyako, FC Grand Capital founder and General Director.
Back to the list of publications
FC Grand Capital maintains its leading position in the Russian pharma market
26 february 2025
This is evidenced by the rating by RNC Pharma based on market data and results of pharma distributors' operations in Russia in 2024.
The research states that FC Grand Capital's sales grew significantly in 2024 compared to 2023, both in public and corporate sectors, allowing the Company to maintain its standing as a top 5 Russian pharma distributor.
According to FC Grand Capital Deputy General Director Dmitry Varakin, the key factor in his company's success is the professional excellence and experience of its team which quickly reacts to any market changes and use them as opportunities for growth. In 2024, on top of growing sales in the corporate segment, the company made a leap in the public procurement sector, becoming a top 8 distributor in that market.
In 2025, FC Grand Capital will keep creating conditions for improving performance of the preferential drug supply and drug accessibility program for Russian patients.
Source: RNC Pharma®: Russian Pharma Distributors Rating
19 february 2025
Lydia Narkaitis, Commercial Director, Department for Public Procurement Development, FC Grand Capital: In the current market conditions, government preferences are vital not only for pharma and medical devices producers, but for large distributors as well. Interview for Pravo na Zdorovye Telegram channel.